AstraZeneca(US:AZN) 智通财经网·2025-10-20 09:00Core Insights - AstraZeneca (AZN.US) and Daiichi Sankyo's cancer drug Enhertu shows improved treatment outcomes for early-stage breast cancer patients, potentially expanding its patient base and moving closer to a cure [1] - Enhertu outperformed Roche's Kadcyla in preventing disease recurrence and showed better results when used pre-surgery [1][2] - The collaboration between AstraZeneca and Daiichi Sankyo has made Enhertu one of the fastest-growing cancer drugs globally, with sales reaching $3.75 billion last year [1] Group 1 - In a study, over 92% of patients treated with Enhertu were alive and free of invasive disease three years post-surgery, compared to 84% for Kadcyla [2] - Enhertu reduced the risk of death or recurrence by 53%, although it was associated with more cases of interstitial lung disease [2] - Approximately two-thirds of patients treated with Enhertu had no cancer cells remaining in their breast or lymph nodes at surgery, compared to 56% in the standard treatment group [2] Group 2 - The main challenge for doctors is determining whether Enhertu should be used pre- or post-surgery, with some experts favoring post-surgery use [2][3] - AstraZeneca's oncology business executive vice president stated that the data from the trials shows "significant advantages," highlighting the need for further discussion on the optimal timing for Enhertu's use [3]